QIAGEN Expands Partnership with Genome Diagnostics for Development of Tests in Prevention and Personalized Healthcare
Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases
21-Jun-2010 -
QIAGEN announced that it has entered into an agreement with the Dutch molecular diagnostic component supplier Genome Diagnostics which covers the development and commercialization of 6 new tests until 2011. QIAGEN believes that this collaboration will further expand the Company’s testing ...
biomarkers
diagnostic tests
diseases
+9